Neuroendocrine and behavioural responses to opioid receptor-antagonist during heroin detoxification: Relationship with personality traits

International Clinical Psychopharmacology

Volumn 18, Issue 5, 2003, Pages 261-269

  Gerra, Gilberto ^a,d   Ceresini, Simona ^b   Esposito, Assunta ^a   Zaimovic, Amir ^a   Moi, Gabriele ^a   Bussandri, Monica ^a   Raggi, Maria A ^c   Molina, Enzo ^b  

^a Addiction Research Center   (Italy)

^b UNIVERSITY OF PARMA   (Italy)

^c UNIVERSITY OF BOLOGNA   (Italy)

^d Az USL   (Italy)

Author keywords

ACTH; Antisocial personality; Clonidine; Cortisol; Epinephrine; Heroin; Norepinephrine; Withdrawal

Indexed keywords

ADRENALIN; BACLOFEN; CLONIDINE; CORTICOTROPIN; DIAMORPHINE; HYDROCORTISONE; KETOPROFEN; NALOXONE; NALTREXONE; NORADRENALIN; OXAZEPAM;

ADULT; ANTISOCIAL BEHAVIOR; ARTICLE; BLOOD PRESSURE; CLINICAL ARTICLE; CLINICAL FEATURE; COMORBIDITY; DEPRESSION; DISEASE ASSOCIATION; DRUG DEPENDENCE; DRUG DETOXIFICATION; DRUG EFFICACY; DRUG SCREENING; HEART RATE; HEMODYNAMICS; HORMONAL REGULATION; HUMAN; MALE; MOOD; NEUROENDOCRINE SYSTEM; OBSESSIVE COMPULSIVE DISORDER; PATIENT ATTITUDE; PERSONALITY DISORDER; POSTTRAUMATIC STRESS DISORDER; PREDICTION; PRIORITY JOURNAL; PSYCHOPATHY; TIME SERIES ANALYSIS; TREATMENT OUTCOME; WITHDRAWAL SYNDROME;

ADULT; BLOOD PRESSURE; COMORBIDITY; EPINEPHRINE; HEART RATE; HEROIN DEPENDENCE; HUMANS; HYDROCORTISONE; MALE; NALTREXONE; NARCOTIC ANTAGONISTS; NEUROSECRETORY SYSTEMS; NOREPINEPHRINE; PERSONALITY DISORDERS; SUBSTANCE WITHDRAWAL SYNDROME; TREATMENT OUTCOME;

EID: 0041328008     PISSN: 02681315     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004850-200309000-00002     Document Type: Article

References (40)

1. Aghajanian GK (1982). Central noradrenergic neurons: a locus for the functional interplay between alpha-2-noradrenoreceptors and opiate receptors. J Clin Psychiatry 43:20-24.
2. Arndt IO, McLellan AT, Dorozynsky L, Woody GE, O'Brien CP (1994). Desipramine treatment for cocaine dependence. Role of antisocial personality disorder. J Nerv Ment Dis 182:151-156.
3. Bell JR, Young MR, Masterman SC, Morris A, Mattick RP, Bammer G (1999). A pilot study of naltrexone-accelerated detoxification in opioid dependence. Med J Aust 171:26-30.
4. Broers B, Giner F, Dumont P, Mino A (2000). Inpatient opiate detoxification in Geneva: follow-up at 1 and 6 months. Drug Alcohol Depend 58:85-92.
5. Buss AH, Durkee A (1957). An inventory for assessing different kinds of hostility. J Consult Psychol 21:343-349.
6. Cami J, Gilabert M, San L, de la Torre R (1992). Hypercortisolism after opioid discontinuation in rapid detoxification of heroin addicts. Br J Addict 87:1145-1151.
7. Elman I, D'Ambra MN, Krause S, Breiter H, Kane M, Morris R, et al. (2001). Ultrarapid opioid detoxification: effects on cardiopulmonary physiology, stress hormones and clinical outcomes. Drug Alcohol Depend 61:163-172.
8. Fava M, Guaraldi GB, Mazzi F, Rigatelli M (1993). Intervista Clinica Strutturata per il DSM-III-R. Florence: Organizzazioni Speciali.
9. Franken IH, Hendriks VM (1999). Predicting outcome of inpatient detoxification of substance abusers. Psychiatr Serv 50:813-817.
10. Gerra G, Caccavari R, Reali N, Bonvicini P, Marcato A, Fertonani G, et al. (1993). Noradrenergic and hormonal responses to physical exercise in adolescents. Relationship to anxiety and tolerance to frustration. Neuropsychobiology 27:65-71.
11. Gerra G, Caccavari R, Fontanesi B, Delsignore R, Fertonani AG, Marcato A, et al. (1994a). Alpha-2-adrenoreceptors sensitivity in heroin addicts with and without previous attention deficit disorder/hyperactivity and conduct disorder. Neuropsychobiology 30:15-19.
12. Gerra G, Caccavari R, Marcato A, Zaimovic A, Avanzini P, Monica C, et al. (1994b). Alpha-1 and -2 adrenoceptor subsensitivity in siblings of opioid addicts with personality disorders and depression. Acta Psychiatr Scand 90:269-273.
13. Gerra G, Marcato A, Caccavari R, Fontanesi B, Delsignore R, Fertonani G, et al. (1995). Clonidine and opiate receptor antagonists in the treatment of heroin addiction. J Subst Abuse Treat 12:35-41.
14. Gerra G, Zaimovic A, Avanzini P, Chittolini B, Giucastro G, Caccavari R, et al. (1997). Neurotransmitter-neuroendocrine responses to experimentally induced aggression in humans: influence of personality variable. Psychiatry Res 66:33-43.
15. Gerra G, Zaimovic A, Rustichelli P, Fontanesi B, Zambelli U, Timpano M, et al. (2000). Rapid opiate detoxication in outpatient treatment: relationship with naltrexone compliance. J Subst Abuse Treat 18:185-191.
16. Gerra G, Zaimovic A, Moi G, Bussandri M, Delsignore R, Caccavari R, Brambilla F (2003). Neuroendocrine correlates of antisocial personality disorder in abstinent heroin dependent subjects. Addict Biol 8(1)Mar:23-32
17. Gordon AJ, Wentz CM, Gibbon JL, Mason AD, Freyder PJ, O'Toole TP (2001). Relationships between patient characteristics and unsuccessful substance abuse detoxification. J Addict Dis 20:41-53.
18. Hathaway SR, McKinley JC (1989). Minnesota Multifasic Personality Inventory-2 Manual Minneapolis: University of Minnesota Minneapolis.
19. Kienbaum P, Thurauf N, Michel MC, Scherbaum N, Gastpar M, Peters J (1998). Profound increase in epinephrine concentration in plasma and cardiovascular stimulation after mu-opioid receptor blockade in opioid-addicted patients during barbiturate-induced anesthesia for acute detoxification. Aneathesiology 88:1154-1161.
20. Kienbaum P, Scherbaum N, Thurauf N, Michel MC, Gastpar M, Peters J (2000). Acute detoxification of opioid-addicted patients with naloxone during propofol or methohexital anesthesia: a comparison of withdrawal symptoms, neuroendocrine, metabolic, and cardiovascular patterns. Crit Care Med 28:969-976.
21. Kienbaum P, Heuter T, Michel MC, Scherbaum N, Gastpar M, Peters J (2002). Sympathetic neural activation evoked by mu-receptor blockade in patients addicted to opioids is abolished by intravenous clonidine. Anesthesiology 96:346-351.
22. King VL, Kidorf MS, Stoller KB, Carter JA, Brooner RK. (2001). Influence of antisocial personality subtypes on drug abuse treatment response. J Nerv Ment Dis 189:593-601.
23. Mayerhofer A, Bartke A, Began T (1993). Catecholamines stimulate testicular steroidogenesis in vitro in the Siberian hamster, Phodopus sungorus. Biol Reprod 48:883-888.
24. McDonald T, Hoffman WE, Berkowitz R, Cunningham F, Cooke B (1999). Heart rate variability and plasma catecholamines in patients during opioid detoxification. J Neurosurg Anesthesiol 11:195-199.
25. McNair DM, Lorr M, Droppleman LF (1971). Profile of Mood States (Manual). San Diego: Educational and Industrial Testing Services.
26. Menzaghi F, Rassnick S, Heinrichs S, Baldwin H, Pich EM, Weiss F, Koob GF (1994). The role of corticotropin-releasing factor in the anxiogenic effects of ethanol withdrawal. Ann NY Acad Sci 739:176-184.
27. Morrison SF, Cao WH (2000). Different adrenal sympathetic preganglionic neurons regulate epinephrine and norepinephrine secretion. Am J Physiol Regul Integr Comp Physiol 279:R1763-R1775.
28. Netter P, Henning J, Roed IS. Serotonin and dopamine as mediators of sensation seeking behavior. Neurpsychobiology 34:155-165.
29. Pacak K (2000). Stressor-specific activation of the hypothalamic-pituitary-adrenocortical axis. Physiol Res 490 (suppl 1):S11-S17.
30. Pasquali R, Vicennati V, Calzoni F, Gnudi U, Gambineri A, Ceroni L, et al. (2000). alpha2-adrenoceptor regulation of the hypothalamic-pituitary-adrenocortical axis in obesity. Clin Endocrinol (Oxford) 52:413-421.
31. Pfohl B, Blum N, Zimmerman M, Stangl D (1989). Structured Interwiew for Personality Disorders, rev. edn. Iowa City, IA: University of Iowa.
32. Raggi MA, Sabbioni C, Casamenti G, Gerra G, Calonghi N, Masotti L (1999). Determination of catecholamines in human plasma by high-performance liquid chromatography with electrochemical detection, J Chromatogr B Biomed Sci Appl 730:201-211.
33. Rao U, Ryan ND, Dahl RE, Birmaher B, Rao R, Williamson DE, Perel JM (1999). Factors associated with the development of substance use disorder in depressed adolescents. J Am Acad Child Adolesc Psychiatry 38:1109-1117.
34. Roy A, Linnoila M (1989). CSF studies on alcoholism and related behaviours. Prog Neuropsychopharmacol Biol Psychiatry 13:505-511.
35. Samochowiec J, Lesch KP, Rottmann M, Smolka M, Syagailo YV, Okladnova O, et al. (1999). Association of a regulatory polymorphism in the promoter region of the monoamine oxidase A gene with antisocial alcoholism. Psychiatry Res 86:67-72.
36. Sarnyai Z, Shaham Y, Heinrichs SC (2001). The role of corticotropin-releasing factor in drug addiction. Pharmacol Rev 53:209-243.
37. Spitzer RL, Williams JBW, Gibbon M, First MB (1990.) Sructured Clinical Inteview According to DSM-III-R. American Washington, DC: Psychiatric Press.
38. Wen HL, Ho WK, Wong HK, Mehal ZD, Ng YH, Ma L (1979). Changes in adrenocorticotropic hormone (ACTH) and cortisol levels in drug addicts treated by a new and rapid detoxification procedure using acupuncture and naloxone. Comp Med East West 6:241-245.
39. Wyatt PJ, Portnoy B, Kupfer DJ, Snyder F (1971). Engelman Resting plasma catecholamine concentrations in patients with depression and anxiety. Arch Gen Psychiatry 24:65-70.
40. Zuckerman M (1994). Biological bases. In: Zuckerman M (editor): Behavioral Expressions and Biosocial Bases of Sensation Seeking, New York: Cambridge University Press; pp. 285-319.